Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series

CARLSBAD, Calif., July 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that company management will participate in a virtual fireside chat as part of the UBS Biotech Management Live Call Series on July 25, 2025. 

Read more at prnewswire.com